COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.

Autor: Alonso R; Centro Universitario de Esclerosis Múltiple. Hospital Ramos Mejía, Buenos Aires, Argentina; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina., Silva B; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina., Garcea O; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina., Diaz PEC; Hospital Carlos Andrade Maín, Ecuador., Dos Passos GR; Hospital São Lucas - Pontifícia Universidade Católica do Rio Grande do Sul, Brazil., Navarro DAR; Hospital Docente Padre Billini, República Dominicana., Valle LAG; Hospital Militar Escuela Managua, Nicaragua., Salinas LCR; Instituto Hondureño De Seguridad Social, Honduras., Negrotto L; FLENI, Buenos Aires, Argentina., Luetic G; Instituto de Neurociencias de Rosario, Argentina., Tkachuk VA; Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina., Míguez J; Hospital Italiano de Buenos Aires, Argentina., de Bedoya FHD; Departamento de Neurologia, Hospital IMT, Paraguay; Departamento de Neurologia de Diagnóstico Codas Thompson, Paraguay., Goiry LG; Clínica Alemana de Santiago, Chile., Sánchez NER; Hospital Dr. Mario C. Rivas de San Pedro Sula, Honduras., Burgos M; Hospital San Bernardo, Salta, Argentina., Steinberg J; Hospital Británico de Buenos Aires, Argentina., Balbuena ME; Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina., Alvarez PM; Hospital San Rafael, Costa Rica., López PA; Hospital Alemán de Buenos Aires, Argentina., Ysrraelit MC; FLENI, Buenos Aires, Argentina., León RA; Private practice, Venezuela., Cohen AB; MD. Complejo Hospitalario CSS, Panamá., Gracia F; Hospital Santo Tomas, Panamá., Molina O; Policlinica Maracaibo, Venezuela., Casas M; Hospital J. M. Ramos Mejia., Deri NH; Diabaid, Buenos Aires, Argentina., Pappolla A; Hospital Italiano de Buenos Aires, Argentina., Patrucco L; Hospital Italiano de Buenos Aires, Argentina., Cristiano E; Centro de esclerosis múltiple de Buenos Aires, Argentina., Tavolini D; INECO Neurociencias Oroño - Rosario, Argentina., Nadur D; Hospital Naval - Hospital de Clínicas, Buenos Aires, Argentina., Granda AMT; Hospital José Carrasco Arteaga, Ecuador., Weiser R; Hospital Horacio Oduber, Aruba., Cassará FP; Hospital Universitario Austral, Buenos Aires, Argentina; Fundación Favaloro, Buenos Aires, Argentina., Sinay V; Fundación Favaloro, Buenos Aires, Argentina., Rodríguez CC; Universidad Catolica de Chile, Chile., Lazaro LG; Servicio de Neurología, Hospital Universitario Sanatorio Guemes, Argentina., Menichini ML; Sanatorio Británico de Rosario, Argentina., Piedrabuena R; Clinica Reina Fabiola, Córdoba, Argentina; Instituto Lennox, Córdoba, Argentina., Escobar GO; Hosp.Patrocinio P.Ruiz,San Cristóbal, Venezuela., Carrá A; Hospital Británico de Buenos Aires, Argentina., Chertcoff A; Hospital Británico de Buenos Aires, Argentina., Pujols BS; Hospital Regional Universitario José Ma Cabral y Báez., Vrech C; Sanatorio Allende, Córdoba, Argentina., Tarulla A; Hospital de Agudos P. Piñero, Buenos Aires, Argentina., Carvajal R; Hospital Universitario Nacional de Colombia., Mainella C; Hospital Español de Rosario, Argentina., Becker J; Hospital São Lucas - Pontifícia Universidade Católica do Rio Grande do Sul, Brazil., Peeters LM; University Multiple Sclerosis Center; Biomedical Research Institute & Data Science Institute, Hasselt University, Belgium., Walton C; MS International Federation, London, UK., Serena MA; Hospital Italiano de Buenos Aires, Argentina., Nuñez S; Infectious Diseases Unit Sanatorio Güemes, Buenos Aires, Argentina., Rojas JI; Centro de esclerosis múltiple de Buenos Aires, Argentina; Servicio de Neurología, Hospital Universitario de CEMIC, Buenos Aires, Argentina.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Jun; Vol. 51, pp. 102886. Date of Electronic Publication: 2021 Mar 07.
DOI: 10.1016/j.msard.2021.102886
Abstrakt: Background: There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America.
Objective: The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19.
Methods: RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either: (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a nasopharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations/intensive critical units (ICU) admission.
Results: 145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization/ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p=<0.001), increased EDSS (5.5 vs 2.9, p=0.0012) and disease duration (18.5 vs. 10.3 years, p=0.001) were significantly associated with hospitalization/ICU.
Conclusion: we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.
Competing Interests: Disclosure of conflicts of interest Edgardo Cristiano has received fees for consultations as a scientific advisory board member and for travel to meetings, conferences, and clinical trials of the following companies: Avanir, Bayer, Biogen, Merck, Novartis, Roche and Teva. Juan Ignacio Rojas has received honoraria from Novartis as a scientific advisor. He has received travel grants and attended courses and conferences on behalf of Merck-Serono Argentina, Novartis Argentina. Liliana Patrucco has received honoraria for scientific and research grants from Teva Tuteur, Merck Serono, Biogen Idec, and Bayer Schering. Ricardo Alonso and Berenice Silva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Merck Serono, Novartis, Sanofi -Genzyme and Roche. Orlando Garcea has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Merck Serono, Novartis, Sanofi -Genzyme and Roche. Liesbet M. Peeters has no personal pecuniary interests to disclose, other than being the chair of The MS Data Alliance (MSDA), which receives income from a range of corporate sponsors, recently including: Biogen, BristolMyersSquibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, Roche. The rest of authors declares no conflict of interest with the study project.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: